Ms. Joyce Liu possesses over 27 years of experience in the pharmaceutical industry, demonstrating profound expertise in multinational corporate management and Regulatory Affairs. Prior to joining Chengdu New Radiomedicine Technology Co., Ltd., she assumed senior positions such as Vice President and Head of Regulatory Affairs, Greater China at Takeda; Executive Director of Regulatory Affairs and Pharmacovigilance at JW Therapeutics; Director of Regulatory Affairs at Sanofi Genzyme China; and Associate Director, Regulatory Affairs/New Product Introduction at Johnson & Johnson.

She has spearheaded the development and implementation of registration strategies and submissions for numerous small - molecule and biologic products across Oncology, GI, Immunology, Neuroscience, Rare Diseases, and Cell Therapy etc. Under her leadership, several innovative products obtained successful regulatory approvals from the FDA and NMPA through the MRCT strategy. She has played a pivotal role in introducing therapies that address unmet clinical needs to China and in promoting the market entry of innovative cell therapies. 

Ms. Joyce Liu currently serves on the DIA China Advisory Committee and holds the position of Deputy Chair of the Regulatory Science Professional Committee.